Advances in Liquid Biopsy shared a post on LinkedIn:
“The program for the Global Virtual Liquid Biopsy Symposium on February 10, 2026 is now live!
This premier online event unites leading international experts to showcase the latest breakthroughs in liquid biopsy research and its clinical translation for cancer diagnostics and precision medicine.
Key highlights include:
State-of-the-art overviews and industry perspectives
Cutting-edge topics: methylation markers with digital PCR, ctDNA in colorectal cancer, gene fusion detection, liquid biopsy for brain tumors, point-of-care diagnostics, pancreatic cancer stratification, and CTC apheresis for functional/single-cell oncology
Strong focus on bridging research to real-world clinical practice for improved early detection, monitoring, prognosis, treatment selection, and personalized care.
Featuring pioneering figures like Prof. Klaus Pantel (a widely recognized founder in the field, with landmark contributions to circulating tumor cells and liquid biopsy concepts) and other trailblazers, Catherine Alix-Panabières, Jürgen Scheuenpflug, Valerie Taly, Sven Borchmann, Leonora Balaj, Stefano Cinti, Milana Frenkel-Morgenstern, med. Georg Weber, Remond Fijneman and Melanie Janning, who have shaped this transformative approach into a cornerstone of modern oncology.
Join us on February 10, 2026 (12:30 pm – 18:40 pm, Central European Time) to hear directly from these experts driving clinical translation across multiple cancer types, and influencing global guidelines.
Excited to connect and discuss the future of liquid biopsy!”
Catherine Alix-Panabières, Director of the Laboratory of Rare Human Circulating Cells and Professor of Universities – Hospital Practitioner at Montpellier University Hospital, shared Advances in Liquid Biopsy’s post on LinkedIn, adding:
“It is a great honor to take part digitally in this meeting bringing together leading pioneers in Liquid Biopsy.
I am sincerely grateful for the invitation and very much look forward to engaging in discussions on the future directions of our field.”
More posts featuring Catherine Alix-Panabières on OncoDaily.